| 213 |
195: Inhibition, NMDARs |
52: Decreased, Calcium influx |
Nov 29, 2016 |
Apr 7, 2018 |
2 AOPs
|
| 214 |
195: Inhibition, NMDARs |
341: Impairment, Learning and memory |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 215 |
195: Inhibition, NMDARs |
191: Neuronal dysfunction |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 228 |
201: Binding of antagonist, NMDA receptors |
341: Impairment, Learning and memory |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 229 |
201: Binding of antagonist, NMDA receptors |
195: Inhibition, NMDARs |
Nov 29, 2016 |
Jun 13, 2018 |
2 AOPs
|
| 236 |
209: Peptide Oxidation |
134: Increase, Kupffer cell activation |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 242 |
213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
21: Altered regulation, Alpha hemoglobin |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 243 |
213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
118: Formation, Formation of hemoglobin adducts |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 245 |
213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
250: Damaging, Red blood cells; hemolysis |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 248 |
214: Bile accumulation, Pathological condition |
288: Activation of specific nuclear receptors, Transcriptional change |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 252 |
219: Reduction, Plasma 17beta-estradiol concentrations |
285: Reduction, Vitellogenin synthesis in liver |
Nov 29, 2016 |
Mar 20, 2017 |
5 AOPs
|
| 253 |
219: Reduction, Plasma 17beta-estradiol concentrations |
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 254 |
220: Increase, Plasma vitellogenin concentrations |
252: Increase, Renal pathology due to VTG deposition |
Nov 29, 2016 |
Jun 24, 2024 |
2 AOPs
|
| 255 |
221: Reduction, Plasma vitellogenin concentrations |
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
Nov 29, 2016 |
Mar 20, 2017 |
9 AOPs
|
| 257 |
231: Decreased, PPAR-alpha activation |
140: Decreased, HSD17B10 expression |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 259 |
232: Decreased, PPAR-beta activation |
140: Decreased, HSD17B10 expression |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 260 |
233: Decreased, PPAR-gamma activation |
140: Decreased, HSD17B10 expression |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 261 |
238: Induction, Pre-mature molting |
328: Decrease, Fecundity |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 262 |
238: Induction, Pre-mature molting |
350: Increase, Mortality |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 263 |
238: Induction, Pre-mature molting |
351: Increased Mortality |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 266 |
240: Feminisation or incomplete development, Primary and accessory male sex organs |
337: N/A, Impairment of reproductive capacity |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 268 |
243: Reduction, Prostaglandin E2 concentration |
119: N/A, Gap |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 269 |
244: Alkylation, Protein |
55: Cell injury/death |
Nov 29, 2016 |
Nov 29, 2016 |
1 AOP
|
| 271 |
244: Alkylation, Protein |
209: Peptide Oxidation |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 272 |
246: Increase, RBC congestion in liver |
173: N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|